Global Pneumococcal Conjugate Vaccine (PCV) Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Page: 83

Published Date: 15 Jan 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global Pneumococcal Conjugate Vaccine (PCV) market size was valued at USD 4257.8 million in 2023 and is forecast to a readjusted size of USD 5258.8 million by 2030 with a CAGR of 3.1% during review period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Pneumococcal Conjugate Vaccine (PCV) industry chain, the market status of Child (23-valent Vaccine, 10-valent Vaccine), Adult (23-valent Vaccine, 10-valent Vaccine), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Pneumococcal Conjugate Vaccine (PCV).

Regionally, the report analyzes the Pneumococcal Conjugate Vaccine (PCV) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Pneumococcal Conjugate Vaccine (PCV) market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Pneumococcal Conjugate Vaccine (PCV) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Pneumococcal Conjugate Vaccine (PCV) industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., 23-valent Vaccine, 10-valent Vaccine).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Pneumococcal Conjugate Vaccine (PCV) market.

Regional Analysis: The report involves examining the Pneumococcal Conjugate Vaccine (PCV) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Pneumococcal Conjugate Vaccine (PCV) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Pneumococcal Conjugate Vaccine (PCV):
Company Analysis: Report covers individual Pneumococcal Conjugate Vaccine (PCV) players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Pneumococcal Conjugate Vaccine (PCV) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Child, Adult).

Technology Analysis: Report covers specific technologies relevant to Pneumococcal Conjugate Vaccine (PCV). It assesses the current state, advancements, and potential future developments in Pneumococcal Conjugate Vaccine (PCV) areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Pneumococcal Conjugate Vaccine (PCV) market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Pneumococcal Conjugate Vaccine (PCV) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type
23-valent Vaccine
10-valent Vaccine
7-valent Vaccine
13-valent Vaccine

Market segment by Application
Child
Adult

Market segment by players, this report covers
Pfizer
GSK
Sanofi
Merck
Walvax Biotechnology
Royal (Wuxi) Bio-Pharmaceutical
Zhifei Biologic
Serum Institute of India

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Pneumococcal Conjugate Vaccine (PCV) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Pneumococcal Conjugate Vaccine (PCV), with revenue, gross margin and global market share of Pneumococcal Conjugate Vaccine (PCV) from 2019 to 2024.
Chapter 3, the Pneumococcal Conjugate Vaccine (PCV) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Pneumococcal Conjugate Vaccine (PCV) market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Pneumococcal Conjugate Vaccine (PCV).
Chapter 13, to describe Pneumococcal Conjugate Vaccine (PCV) research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Pneumococcal Conjugate Vaccine (PCV)
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Pneumococcal Conjugate Vaccine (PCV) by Type
        1.3.1 Overview: Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Type in 2023
        1.3.3 23-valent Vaccine
        1.3.4 10-valent Vaccine
        1.3.5 7-valent Vaccine
        1.3.6 13-valent Vaccine
    1.4 Global Pneumococcal Conjugate Vaccine (PCV) Market by Application
        1.4.1 Overview: Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Child
        1.4.3 Adult
    1.5 Global Pneumococcal Conjugate Vaccine (PCV) Market Size & Forecast
    1.6 Global Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast by Region
        1.6.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region: 2019 VS 2023 VS 2030
        1.6.2 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region, (2019-2030)
        1.6.3 North America Pneumococcal Conjugate Vaccine (PCV) Market Size and Prospect (2019-2030)
        1.6.4 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size and Prospect (2019-2030)
        1.6.5 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size and Prospect (2019-2030)
        1.6.6 South America Pneumococcal Conjugate Vaccine (PCV) Market Size and Prospect (2019-2030)
        1.6.7 Middle East and Africa Pneumococcal Conjugate Vaccine (PCV) Market Size and Prospect (2019-2030)

2 Company Profiles
    2.1 Pfizer
        2.1.1 Pfizer Details
        2.1.2 Pfizer Major Business
        2.1.3 Pfizer Pneumococcal Conjugate Vaccine (PCV) Product and Solutions
        2.1.4 Pfizer Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Pfizer Recent Developments and Future Plans
    2.2 GSK
        2.2.1 GSK Details
        2.2.2 GSK Major Business
        2.2.3 GSK Pneumococcal Conjugate Vaccine (PCV) Product and Solutions
        2.2.4 GSK Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 GSK Recent Developments and Future Plans
    2.3 Sanofi
        2.3.1 Sanofi Details
        2.3.2 Sanofi Major Business
        2.3.3 Sanofi Pneumococcal Conjugate Vaccine (PCV) Product and Solutions
        2.3.4 Sanofi Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Sanofi Recent Developments and Future Plans
    2.4 Merck
        2.4.1 Merck Details
        2.4.2 Merck Major Business
        2.4.3 Merck Pneumococcal Conjugate Vaccine (PCV) Product and Solutions
        2.4.4 Merck Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Merck Recent Developments and Future Plans
    2.5 Walvax Biotechnology
        2.5.1 Walvax Biotechnology Details
        2.5.2 Walvax Biotechnology Major Business
        2.5.3 Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Product and Solutions
        2.5.4 Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Walvax Biotechnology Recent Developments and Future Plans
    2.6 Royal (Wuxi) Bio-Pharmaceutical
        2.6.1 Royal (Wuxi) Bio-Pharmaceutical Details
        2.6.2 Royal (Wuxi) Bio-Pharmaceutical Major Business
        2.6.3 Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Product and Solutions
        2.6.4 Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments and Future Plans
    2.7 Zhifei Biologic
        2.7.1 Zhifei Biologic Details
        2.7.2 Zhifei Biologic Major Business
        2.7.3 Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Product and Solutions
        2.7.4 Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Zhifei Biologic Recent Developments and Future Plans
    2.8 Serum Institute of India
        2.8.1 Serum Institute of India Details
        2.8.2 Serum Institute of India Major Business
        2.8.3 Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Product and Solutions
        2.8.4 Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Serum Institute of India Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Pneumococcal Conjugate Vaccine (PCV) Revenue and Share by Players (2019-2024)
    3.2 Market Share Analysis (2023)
        3.2.1 Market Share of Pneumococcal Conjugate Vaccine (PCV) by Company Revenue
        3.2.2 Top 3 Pneumococcal Conjugate Vaccine (PCV) Players Market Share in 2023
        3.2.3 Top 6 Pneumococcal Conjugate Vaccine (PCV) Players Market Share in 2023
    3.3 Pneumococcal Conjugate Vaccine (PCV) Market: Overall Company Footprint Analysis
        3.3.1 Pneumococcal Conjugate Vaccine (PCV) Market: Region Footprint
        3.3.2 Pneumococcal Conjugate Vaccine (PCV) Market: Company Product Type Footprint
        3.3.3 Pneumococcal Conjugate Vaccine (PCV) Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value and Market Share by Type (2019-2024)
    4.2 Global Pneumococcal Conjugate Vaccine (PCV) Market Forecast by Type (2025-2030)

5 Market Size Segment by Application
    5.1 Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Application (2019-2024)
    5.2 Global Pneumococcal Conjugate Vaccine (PCV) Market Forecast by Application (2025-2030)

6 North America
    6.1 North America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type (2019-2030)
    6.2 North America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application (2019-2030)
    6.3 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country
        6.3.1 North America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Country (2019-2030)
        6.3.2 United States Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)
        6.3.3 Canada Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)
        6.3.4 Mexico Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)

7 Europe
    7.1 Europe Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type (2019-2030)
    7.2 Europe Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application (2019-2030)
    7.3 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country
        7.3.1 Europe Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Country (2019-2030)
        7.3.2 Germany Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)
        7.3.3 France Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)
        7.3.4 United Kingdom Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)
        7.3.5 Russia Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)
        7.3.6 Italy Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)

8 Asia-Pacific
    8.1 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type (2019-2030)
    8.2 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application (2019-2030)
    8.3 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size by Region
        8.3.1 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Region (2019-2030)
        8.3.2 China Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)
        8.3.3 Japan Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)
        8.3.4 South Korea Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)
        8.3.5 India Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)
        8.3.6 Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)
        8.3.7 Australia Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)

9 South America
    9.1 South America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type (2019-2030)
    9.2 South America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application (2019-2030)
    9.3 South America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country
        9.3.1 South America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Country (2019-2030)
        9.3.2 Brazil Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)
        9.3.3 Argentina Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)

10 Middle East & Africa
    10.1 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type (2019-2030)
    10.2 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application (2019-2030)
    10.3 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country
        10.3.1 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Country (2019-2030)
        10.3.2 Turkey Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)
        10.3.3 Saudi Arabia Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)
        10.3.4 UAE Pneumococcal Conjugate Vaccine (PCV) Market Size and Forecast (2019-2030)

11 Market Dynamics
    11.1 Pneumococcal Conjugate Vaccine (PCV) Market Drivers
    11.2 Pneumococcal Conjugate Vaccine (PCV) Market Restraints
    11.3 Pneumococcal Conjugate Vaccine (PCV) Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 Pneumococcal Conjugate Vaccine (PCV) Industry Chain
    12.2 Pneumococcal Conjugate Vaccine (PCV) Upstream Analysis
    12.3 Pneumococcal Conjugate Vaccine (PCV) Midstream Analysis
    12.4 Pneumococcal Conjugate Vaccine (PCV) Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Region (2019-2024) & (USD Million)
    Table 4. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Region (2025-2030) & (USD Million)
    Table 5. Pfizer Company Information, Head Office, and Major Competitors
    Table 6. Pfizer Major Business
    Table 7. Pfizer Pneumococcal Conjugate Vaccine (PCV) Product and Solutions
    Table 8. Pfizer Pneumococcal Conjugate Vaccine (PCV) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 9. Pfizer Recent Developments and Future Plans
    Table 10. GSK Company Information, Head Office, and Major Competitors
    Table 11. GSK Major Business
    Table 12. GSK Pneumococcal Conjugate Vaccine (PCV) Product and Solutions
    Table 13. GSK Pneumococcal Conjugate Vaccine (PCV) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 14. GSK Recent Developments and Future Plans
    Table 15. Sanofi Company Information, Head Office, and Major Competitors
    Table 16. Sanofi Major Business
    Table 17. Sanofi Pneumococcal Conjugate Vaccine (PCV) Product and Solutions
    Table 18. Sanofi Pneumococcal Conjugate Vaccine (PCV) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 19. Sanofi Recent Developments and Future Plans
    Table 20. Merck Company Information, Head Office, and Major Competitors
    Table 21. Merck Major Business
    Table 22. Merck Pneumococcal Conjugate Vaccine (PCV) Product and Solutions
    Table 23. Merck Pneumococcal Conjugate Vaccine (PCV) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 24. Merck Recent Developments and Future Plans
    Table 25. Walvax Biotechnology Company Information, Head Office, and Major Competitors
    Table 26. Walvax Biotechnology Major Business
    Table 27. Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Product and Solutions
    Table 28. Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 29. Walvax Biotechnology Recent Developments and Future Plans
    Table 30. Royal (Wuxi) Bio-Pharmaceutical Company Information, Head Office, and Major Competitors
    Table 31. Royal (Wuxi) Bio-Pharmaceutical Major Business
    Table 32. Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Product and Solutions
    Table 33. Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 34. Royal (Wuxi) Bio-Pharmaceutical Recent Developments and Future Plans
    Table 35. Zhifei Biologic Company Information, Head Office, and Major Competitors
    Table 36. Zhifei Biologic Major Business
    Table 37. Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Product and Solutions
    Table 38. Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 39. Zhifei Biologic Recent Developments and Future Plans
    Table 40. Serum Institute of India Company Information, Head Office, and Major Competitors
    Table 41. Serum Institute of India Major Business
    Table 42. Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Product and Solutions
    Table 43. Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 44. Serum Institute of India Recent Developments and Future Plans
    Table 45. Global Pneumococcal Conjugate Vaccine (PCV) Revenue (USD Million) by Players (2019-2024)
    Table 46. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Players (2019-2024)
    Table 47. Breakdown of Pneumococcal Conjugate Vaccine (PCV) by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 48. Market Position of Players in Pneumococcal Conjugate Vaccine (PCV), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
    Table 49. Head Office of Key Pneumococcal Conjugate Vaccine (PCV) Players
    Table 50. Pneumococcal Conjugate Vaccine (PCV) Market: Company Product Type Footprint
    Table 51. Pneumococcal Conjugate Vaccine (PCV) Market: Company Product Application Footprint
    Table 52. Pneumococcal Conjugate Vaccine (PCV) New Market Entrants and Barriers to Market Entry
    Table 53. Pneumococcal Conjugate Vaccine (PCV) Mergers, Acquisition, Agreements, and Collaborations
    Table 54. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value (USD Million) by Type (2019-2024)
    Table 55. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value Share by Type (2019-2024)
    Table 56. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value Forecast by Type (2025-2030)
    Table 57. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application (2019-2024)
    Table 58. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value Forecast by Application (2025-2030)
    Table 59. North America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type (2019-2024) & (USD Million)
    Table 60. North America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type (2025-2030) & (USD Million)
    Table 61. North America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application (2019-2024) & (USD Million)
    Table 62. North America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application (2025-2030) & (USD Million)
    Table 63. North America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Country (2019-2024) & (USD Million)
    Table 64. North America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Country (2025-2030) & (USD Million)
    Table 65. Europe Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type (2019-2024) & (USD Million)
    Table 66. Europe Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type (2025-2030) & (USD Million)
    Table 67. Europe Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application (2019-2024) & (USD Million)
    Table 68. Europe Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application (2025-2030) & (USD Million)
    Table 69. Europe Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Country (2019-2024) & (USD Million)
    Table 70. Europe Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Country (2025-2030) & (USD Million)
    Table 71. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type (2019-2024) & (USD Million)
    Table 72. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type (2025-2030) & (USD Million)
    Table 73. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application (2019-2024) & (USD Million)
    Table 74. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application (2025-2030) & (USD Million)
    Table 75. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Region (2019-2024) & (USD Million)
    Table 76. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Region (2025-2030) & (USD Million)
    Table 77. South America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type (2019-2024) & (USD Million)
    Table 78. South America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type (2025-2030) & (USD Million)
    Table 79. South America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application (2019-2024) & (USD Million)
    Table 80. South America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application (2025-2030) & (USD Million)
    Table 81. South America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Country (2019-2024) & (USD Million)
    Table 82. South America Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Country (2025-2030) & (USD Million)
    Table 83. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type (2019-2024) & (USD Million)
    Table 84. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type (2025-2030) & (USD Million)
    Table 85. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application (2019-2024) & (USD Million)
    Table 86. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Application (2025-2030) & (USD Million)
    Table 87. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Country (2019-2024) & (USD Million)
    Table 88. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Country (2025-2030) & (USD Million)
    Table 89. Pneumococcal Conjugate Vaccine (PCV) Raw Material
    Table 90. Key Suppliers of Pneumococcal Conjugate Vaccine (PCV) Raw Materials
List of Figures
    Figure 1. Pneumococcal Conjugate Vaccine (PCV) Picture
    Figure 2. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Type in 2023
    Figure 4. 23-valent Vaccine
    Figure 5. 10-valent Vaccine
    Figure 6. 7-valent Vaccine
    Figure 7. 13-valent Vaccine
    Figure 8. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 9. Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Application in 2023
    Figure 10. Child Picture
    Figure 11. Adult Picture
    Figure 12. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 13. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 14. Global Market Pneumococcal Conjugate Vaccine (PCV) Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
    Figure 15. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Region (2019-2030)
    Figure 16. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Region in 2023
    Figure 17. North America Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 18. Europe Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 19. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 20. South America Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 21. Middle East and Africa Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 22. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Players in 2023
    Figure 23. Pneumococcal Conjugate Vaccine (PCV) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
    Figure 24. Global Top 3 Players Pneumococcal Conjugate Vaccine (PCV) Market Share in 2023
    Figure 25. Global Top 6 Players Pneumococcal Conjugate Vaccine (PCV) Market Share in 2023
    Figure 26. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value Share by Type (2019-2024)
    Figure 27. Global Pneumococcal Conjugate Vaccine (PCV) Market Share Forecast by Type (2025-2030)
    Figure 28. Global Pneumococcal Conjugate Vaccine (PCV) Consumption Value Share by Application (2019-2024)
    Figure 29. Global Pneumococcal Conjugate Vaccine (PCV) Market Share Forecast by Application (2025-2030)
    Figure 30. North America Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Type (2019-2030)
    Figure 31. North America Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Application (2019-2030)
    Figure 32. North America Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Country (2019-2030)
    Figure 33. United States Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 34. Canada Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 35. Mexico Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 36. Europe Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Type (2019-2030)
    Figure 37. Europe Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Application (2019-2030)
    Figure 38. Europe Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Country (2019-2030)
    Figure 39. Germany Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 40. France Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 41. United Kingdom Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 42. Russia Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 43. Italy Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 44. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Type (2019-2030)
    Figure 45. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Application (2019-2030)
    Figure 46. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Region (2019-2030)
    Figure 47. China Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 48. Japan Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 49. South Korea Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 50. India Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 51. Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 52. Australia Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 53. South America Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Type (2019-2030)
    Figure 54. South America Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Application (2019-2030)
    Figure 55. South America Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Country (2019-2030)
    Figure 56. Brazil Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 57. Argentina Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 58. Middle East and Africa Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Type (2019-2030)
    Figure 59. Middle East and Africa Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Application (2019-2030)
    Figure 60. Middle East and Africa Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Country (2019-2030)
    Figure 61. Turkey Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 62. Saudi Arabia Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 63. UAE Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2019-2030) & (USD Million)
    Figure 64. Pneumococcal Conjugate Vaccine (PCV) Market Drivers
    Figure 65. Pneumococcal Conjugate Vaccine (PCV) Market Restraints
    Figure 66. Pneumococcal Conjugate Vaccine (PCV) Market Trends
    Figure 67. Porters Five Forces Analysis
    Figure 68. Manufacturing Cost Structure Analysis of Pneumococcal Conjugate Vaccine (PCV) in 2023
    Figure 69. Manufacturing Process Analysis of Pneumococcal Conjugate Vaccine (PCV)
    Figure 70. Pneumococcal Conjugate Vaccine (PCV) Industrial Chain
    Figure 71. Methodology
    Figure 72. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Pfizer
GSK
Sanofi
Merck
Walvax Biotechnology
Royal (Wuxi) Bio-Pharmaceutical
Zhifei Biologic
Serum Institute of India

Related Reports

Global Pneumococcal Conjugate Vaccine (PCV) Supply, Demand and Key Producers, 2023-2029

Global Pneumococcal Conjugate Vaccine (PCV) Supply, Demand and Key Producers, 2023-2029

date 15 Feb 2023

date Pharma & Healthcare

The global Pneumococcal Conjugate Vaccine (PCV) market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Pneumococcal Conjugate Vaccine (PCV) Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Pneumococcal Conjugate Vaccine (PCV) Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 05 Jan 2023

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Pneumococcal Conjugate Vaccine (PCV) market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Product Tags

Pneumococcal Conjugate Vaccine (PCV)

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>